DSP Clinical Announces New Co-Monitoring Service
DSP Clinical, a full-service CRO managing Phase I to IV clinical trials across many therapeutic areas including infertility, endocrinology, urology, and gastrointestinal studies, announced a new co-monitoring service that provides flexible, cost-effective monitoring support to help clinical trials meet study timelines.
The service, which scales to fit the size, complexity, and speed of Phase I–IV research clinical trials in any therapeutic area, can provide back-up monitors who are trained and ready to help. DSP monitors are long-term CCRA-certified employees who are fluent in a variety of EDC systems.
Sponsors can elect to have full- or part-time monitoring help with tasks such as reviewing data, conducting pre-study visits, or preparing for site audits. DSP’s monitors step in as needed, working as an extension of the existing study team while minimizing overhead and lag time. The service is available immediately.
For more information, visit dspclinical.com
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
